Xeris Biopharma Holdings Enters Oversold Territory with RSI Reading of 29.4

Xeris Biopharma Holdings (XERS) has entered oversold territory with an RSI reading of 29.4, after hitting a low of $6.65 per share. This may indicate that the recent heavy selling is exhausting itself and could be a sign for a bullish investor to look for entry points on the buy side. The stock's 52-week range is $3.14 to $10.08 per share.